Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Operating Leases (2019 - 2024)

Historic Operating Leases for Sanofi (SNY) over the last 7 years, with Q2 2025 value amounting to $1.7 billion.

  • Sanofi's Operating Leases fell 756.28% to $1.7 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $1.7 billion, marking a year-over-year decrease of 756.28%. This contributed to the annual value of $1.8 billion for FY2024, which is 1994.85% down from last year.
  • Latest data reveals that Sanofi reported Operating Leases of $1.7 billion as of Q2 2025, which was down 756.28% from $1.8 billion recorded in Q4 2024.
  • In the past 5 years, Sanofi's Operating Leases ranged from a high of $2.4 billion in Q4 2021 and a low of $1.5 billion during Q2 2021
  • Moreover, its 5-year median value for Operating Leases was $2.0 billion (2023), whereas its average is $2.0 billion.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 4339.28% in 2021, then crashed by 1951.87% in 2024.
  • Quarter analysis of 5 years shows Sanofi's Operating Leases stood at $2.4 billion in 2021, then dropped by 7.73% to $2.2 billion in 2022, then dropped by 1.84% to $2.2 billion in 2023, then fell by 19.52% to $1.8 billion in 2024, then fell by 1.86% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q2 2025, $1.8 billion for Q4 2024, and $1.9 billion during Q2 2024.